Imunon Q2 2026: $6.9M Cash, Phase 3 Enrollment on Track, R&D Day Set
IMNN is trading near its 52-week low of $1.47 (15% above the low) on light trading volume (0.3× avg).
Summary
Imunon reported Q2 2026 financial results with $6.9 million in cash and a $2.8 million net loss. Clinical progress continues with Phase 3 enrollment ahead of schedule, but the cash runway is tight, and the company has scheduled an R&D Day for September 23, 2026.
Key Events · Earnings and Guidance · IMNN
-
Q2 2026 Financial Results
Net loss of $2.8 million ($0.54 per share) on operating expenses of $2.8 million. Cash and cash equivalents were $6.9 million as of June 30, 2026, down from $8.8 million at year-end 2025.
-
Cash Runway Pressure
With a quarterly cash burn of approximately $3.5 million, the $6.9 million cash balance provides less than two quarters of runway, highlighting the need for additional financing.
-
Phase 3 Enrollment Progress
Enrollment in the pivotal OVATION 3 trial for IMNN-001 in advanced ovarian cancer is exceeding forecasts, with completion expected by the first half of 2029. The independent Data Monitoring Committee recommended continuation of the trial.
-
Upcoming R&D Day
The company will host an R&D Day on September 23, 2026, in New York, featuring presentations from leading clinical investigators on IMNN-001 and the DNA-mediated immunotherapy platform.
Analysis · IMNN · Life Sciences
Imunon's Q2 2026 financials reveal a net loss of $2.8 million and cash of $6.9 million as of June 30, 2026. With a quarterly burn rate of roughly $3.5 million, the company has less than two quarters of cash runway without additional financing. Encouragingly, a Data Monitoring Committee recommended continuing the Phase 3 OVATION 3 trial, and enrollment is exceeding forecasts. Still, the financial position remains precarious. The upcoming R&D Day on September 23, 2026, could serve as a catalyst for partnership or financing discussions.
At the time of this filing, IMNN was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $1.47 to $7.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.